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ABSTRACT 
 
Endothelial progenitor cells (EPCs) are mobilized into circulation to replace damaged 
endothelial and recapitulate the vascular network of injured tissues. Intracellular Ca2+ signals are key to 
EPC activation, but it is yet to be elucidated whether they are endowed with the same blend of Ca2+-
permeable channels expressed by mature endothelial cells. For instance, endothelial colony forming 
cells (ECFCs), the only EPC subset truly committed to acquire a mature endothelial phenotype, lack 
canonical transient receptor potential channels 3, 5 and 6 (TRPC3, 5 and 6), which are widely 
distributed in vascular endothelium; on the other hand, they express a functional store-operated Ca2+ 
entry (SOCE). The present study was undertaken to assess whether human circulating EPCs possess 
TRP vanilloid channel 4 (TRPV4), which plays a master signalling role in mature endothelium, by 
controlling both vascular remodelling and arterial pressure. We found that EPCs express both TRPV4 
mRNA and protein. Moreover, both GSK1016790A (GSK) and phorbol myristate acetate and, two 
widely employed TRPV4 agonists, induced intracellular Ca2+ signals uniquely in presence of 
extracellular Ca2+. GSK- and PMA-induced Ca2+ elevations were inhibited by RN-1734 and ruthenium 
red, which selectively target TRPV4 in mature endothelium. However, TRPV4 stimulation with GSK 
did not cause EPC proliferation, while the pharmacological blockade of TRPV4 only modestly affected 
EPC growth in the presence of a growth factor-enriched culture medium. Conversely, SOCE inhibition 
with BTP-2, La3+ and Gd3+ dramatically decreased cell proliferation. These data indicate that human 
circulating EPCs possess a functional TRPV4 protein before their engraftment into nascent vessels. 
 
 
 
 
Page 2 of 34
John Wiley & Sons, Inc.
Journal of Cellular Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 3 
INTRODUCTION 
 
Vascular endothelial cells line the lumen of blood and lymphatic thereby forming a 
multifunctional signal transduction platform that maintains cardiovascular homeostasis (Mancardi et 
al., 2011; Moccia et al., 2013b). Endothelial injury is recognized as initial step in the onset of severe 
cardiovascular diseases, including myocardial infarction, brain stroke, atherosclerosis, and diabetes 
(Moccia et al., 2010; Moccia et al., 2012a). Endothelial progenitor cells (EPCs) are a sub-population of 
mononuclear cells (MNCs) which is recruited from either bone marrow (BM) or arterial wall to replace 
damaged/senescent endothelial cells and recapitulate the vascular network of lesioned organs (Yoder, 
2012b). They act by either stimulating local angiogenesis via paracrine signalling or by physically 
engrafting within neovessels (Yoder, 2012b). It is, therefore, not surprising that circulating EPCs are 
currently regarded as one of the most promising tools for the cell-based therapy of CV pathologies 
(Alev et al., 2011; Murasawa and Asahara, 2005). Among the different subtypes of EPCs described in 
the literature (Yoder, 2012a), the so-called endothelial colony forming cells (ECFCs) are unique in 
their truly belonging to the endothelial lineage and in their ability of forming capillary like structures in 
vitro and patent vessels in vivo (Basile and Yoder, 2014; Yoder, 2012b). It is, however, largely 
unknown whether they already express the signal transduction pathways that enable mature endothelial 
cells to properly respond to external stimuli (Lodola et al., 2012; Moccia et al., 2012c; Moccia et al., 
2014b).  
An increase in intracellular Ca2+ concentration ([Ca2+]i) is the earliest response of vascular 
endothelium to extracellular stimulation (Moccia et al., 2012b; Pla et al., 2012a). The endothelial Ca2+ 
signals are mainly shaped by the interplay between inositol-1,4,5-trisphosphate (InsP3)-gated Ca2+ 
release from the endoplasmic reticulum (ER) and Ca2+ influx across the plasma membrane (Moccia et 
al., 2012b; Moccia et al., 2013b). Store-operated Ca2+ entry (SOCE) sustains a myriad of endothelial 
Page 3 of 34
John Wiley & Sons, Inc.
Journal of Cellular Physiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 4 
functions, ranging from cell proliferation to the control of luminal permeability (Abdullaev et al., 2008; 
Moccia et al., 2012b; Tiruppathi et al., 2006). Recent work from our group has disclosed that a 
functional SOCE is also present in human circulating EPCs, where it is mediated by the interaction 
between Stim1, the ER Ca2+ sensor, and Orai1 and canonical transient receptor potential channel 1 
(TRPC1), which contribute to the Ca2+-permeable pore-forming domain on the plasma membrane 
(Lodola et al., 2012; Moccia et al., 2013a; Moccia et al., 2012d; Sánchez-Hernández et al., 2010). 
Store-dependent Ca2+ inflow controls cell proliferation and in vitro tubulogenesis in EPCs isolated 
from both peripheral (Dragoni et al., 2011; Dragoni et al., 2014; Lodola et al., 2012) and umbilical cord 
blood (Dragoni et al., 2013). Conversely, circulating human EPCs lack the diacylglycerol-sensitive 
canonical transient receptor potential (TRP) channels 3 (TRPC3) and TRPC6, and the polymodal 
channel TRPC5 (Fiorio Pla and Munaron, 2014; Moccia et al., 2012b; Pla et al., 2012a). This feature is 
rather surprising when considering the important roles played by these pathways in mature endothelium 
(Fiorio Pla and Munaron, 2014; Moccia et al., 2012b; Moccia et al., 2014a; Pla et al., 2012a). For 
instance, TRPC3 and TRPC6 may sustain the pro-angiogenic Ca2+ response to VEGF in microvascular 
endothelial cells (Cheng et al., 2006; Hamdollah Zadeh et al., 2008). An additional store-independent 
Ca2+ entry route in mature endothelium is provided by vanilloid TRP channel 4 (TRPV4) (Fiorio Pla 
and Gkika, 2013; Hatano et al., 2013; Pla et al., 2012a; Schierling et al., 2011; Troidl et al., 2010; 
Troidl et al., 2009). This is a polymodal TRP channel which acts as a molecular integrator of both 
chemical and physical stimuli (Earley and Brayden, 2010; Moccia et al., 2012b). Endothelial TRPV4 
may be activated by changes in osmotic pressure, fluid shear stress and temperature, by the phorbol 
derivatives, 4α-phorbol-12,13-didecanoate (4αPDD) and phorbol myristate acetate (PMA), by 
arachidonic acid (AA) and its metabolits, and by the specific small molecule agonist, N-((1S)-1-{[4-
((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-
methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A  or GSK) (Baylie and Brayden, 2011; 
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Sonkusare et al., 2012; Sullivan et al., 2012). A growing number of studies revealed that TRPV4-
mediated Ca2+ inflow contributes to endothelial cell proliferation and vascular remodelling (i.e. 
arteriogenesis) which occurs as a consequence of arterial occlusion in a number of vascular districts 
(Hatano et al., 2013; Pla et al., 2008; Pla et al., 2012b; Schierling et al., 2011; Troidl et al., 2010; Troidl 
et al., 2009). Moreover, TRPV4 may regulate arterial pressure by activating a variety of vasodilatory 
mechanisms, such as nitric oxide (NO), prostaglandin I2 (PGI2), and intermediate- and small-
conductance Ca2+-activated K+ channels (IKCa/SKCa)-mediated endothelial-dependent hyperpolarizing 
factor (EDHF) (Baylie and Brayden, 2011; Earley and Brayden, 2010). In the light of the key signalling 
function accomplished by TRPV4 in differentiated endothelial cells, we thus undertook the present 
investigation to assess whether this Ca2+-permeable route in also expressed in human circulating EPCs. 
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MATERIALS AND METHODS 
 
Cell isolation 
Blood samples (40 mL) were obtained from healthy human volunteers aged from 22 to 28 years 
old. The Institutional Review Board at “Istituto di Ricovero e Cura a Carattere Scientifico Policlinico 
San Matteo Foundation” in Pavia approved all protocols and specifically approved the study. Informed 
consent was obtained according to the Declaration of Helsinki. Informed written consent was obtained 
according to the Declaration of Helsinki. We focussed on the so-called endothelial colony forming cells 
(ECFCs) (Ingram et al., 2004), a subgroup of EPCs which are found in the CD34+ CD45- fraction of 
circulating mononuclear cells, exhibit robust proliferative potential and form capillary-like structures in 
vitro (Ingram et al., 2004; Moccia et al., 2012d). To isolate ECFCs, mononuclear cells (MNCs) were 
separated from peripheral blood (PB) by density gradient centrifugation on lymphocyte separation 
medium for 30 min at 400g and washed twice in EBM-2 with 2% FCS. A median of 36 x 106 MNCs 
(range 18-66) were plated on collagen-coated culture dishes (BD Biosciences) in the presence of the 
endothelial cell growth medium EGM-2 MV Bullet Kit (Lonza) containing endothelial basal medium 
(EBM-2), 5% foetal bovine serum, recombinant human (rh) EGF, rhVEGF, rhFGF-B, rhIGF-1, 
ascorbic acid and heparin, and maintained at 37°C in 5% CO2 and humidified atmosph re. Discard of 
non-adherent cells was performed after 2 days; thereafter medium was changed three times a week. The 
outgrowth of endothelial cells from adherent MNCs was characterized by the formation of a cluster of 
cobblestone-appearing cells (Sánchez-Hernández et al., 2010). That ECFC-derived colonies belonged 
to endothelial lineage was confirmed as described in (Sánchez-Hernández et al., 2010) and (Lodola et 
al., 2012). Adult human dermal microvascular endothelial cells (HMVEC-d) and adult human cardiac 
microvascular endothelial cells (HMVEC-c) were purchased from Lonza and grown in EGM2-MV 
medium. Cells were used at passages 3–10. 
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Solutions 
Physiological salt solution (PSS) had the following composition (in mM): 150 NaCl, 6 KCl, 1.5 
CaCl2, 1 MgCl2, 10 Glucose, 10 Hepes. In Ca2+-free solution (0Ca2+), Ca2+ was substituted with 2 mM 
NaCl, and 0.5 mM EGTA was added. Solutions were titrated to pH 7.4 with NaOH. The osmolality of 
the extracellular solution, as measured with an osmometer (Wescor 5500, Logan, UT), was 300-310 
mmol/kg. 
 
[Ca2+]i measurements and statistics 
EPCs were loaded with 4 µM fura-2 acetoxymethyl ester (fura-2/AM; 1 mM stock in dimethyl 
sulfoxide) in PSS for 1 hour at room temperature. The Ca2+ measuring system has been extensively 
described in (Berra-Romani et al., 2013; Di Buduo et al., 2014). The Ca2+ fluorochrome has been 
excited at 340 and 380 nm and the light emitted detected at 510 nm. [Ca2+]i was monitored by 
measuring, for each ROI, the ratio of the mean fluorescence emitted at 510 nm when exciting 
alternatively at 340 and 380 nm (shortly termed "ratio"). An increase in [Ca2+]i causes an increase in 
the ratio (Berra-Romani et al., 2013; Di Buduo et al., 2014). Ratio measurements were performed and 
plotted on-line every 3 s. The experiments were performed at room temperature (22°C). All the data 
have been collected from ECFCs isolated from the peripheral blood of at least three healthy volunteers. 
The amplitude of the peak Ca2+ response was measured as the difference between the ratio at the peak 
and the mean ratio of 1 min baseline before the peak. Pooled data are given as mean ± SE and 
statistical significance (P<0.05) was evaluated by the Student's t-test for unpaired observations. 
 
RNA isolation and RT-PCR  
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Total RNA was extracted from the ECFCs using the QIAzol Lysis Reagent (QIAGEN, Italy). 
Single cDNA was synthesized from RNA (1 µg) using random hexamers and M-MLV Reverse 
Transcriptase (Invitrogen S.R.L., Italy). Reverse transcription was always performed in the presence or 
absence (negative control) of the reverse transcriptase enzyme. PCR was performed as previously 
described by using specific primers (intron-spanning primers) designed for human TRPV4 (sense, 5’-
TCCAGCTGCTCTACTTCATC-3’; antisense, 5’-CTGAAGCGTAGCCGATCAT -3’) and TRPV1 
(sense, 5’-AGCTACTACAAGGGCCAGACA-3’; antisense, 5’-AACTTCACGATGCCCAGCTGG-
3’) (Lodola et al., 2012; Sánchez-Hernández et al., 2010). The RT-PCR reactions were normalized 
using β-actin as housekeeping gene (primers used:Hs_ACTB_1_SG, QuantiTect Primer Assay 
QT00095431, Qiagen). First, the sequence of the TRPV4 band was checked by using the Big dye 
terminator cycle sequencing kit (Applied Biosystem, PE, USA). PCR products were separated with 
agarose gel electrophoresis, stained with ethidium bromide, and acquired with the Image Master VDS 
(Amersham Biosciences Europe, Italy). The molecular weight of the PCR products was compared to 
the DNA molecular weight marker VIII (Roche Molecular Biochemicals, Italy). 
 
Protein extraction and Western blot analysis 
Protein extraction and Western blot analysis were carried out as described previously (Lodola et 
al., 2012; Sánchez-Hernández et al., 2010). The anti-TRPV4 antibody was raised against the peptide C-
DGHQQGYAPKWRAEDAPL in rabbits (Loftstrand Labs). The resulting rabbit serum was then 
affinity purified to obtain the anti-TRPV4 antibody. The specific controls were performed as previously 
described (Pla et al., 2012b). 
 
Proliferation assay 
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A total of 1 x 105 ECFC-derived cells (1st passage) were plated in 30-mm collagen-treated 
dishes in endothelial basal medium (EBM-2; Lonza) supplemented with 5% foetal bovine serum (FBS) 
in the presence of 20 nM GSK. As a control experiment, cells were seeded in the presence of in the 
presence of the endothelial cell growth medium EGM-2 MV Bullet Kit (Lonza) containing EBM-2, 5% 
FBS, recombinant human (rh) EGF, rhVEGF, rhFGF-B, rhIGF-1, ascorbic acid and heparin. Cultures 
were incubated at 37 °C, 5% CO2 and cell growth assessed every day until confluence was reached in 
the control dishes. Cells were then recovered by trypsinization and their number assessed by counting 
in a hemocytometer. The percentage of growth stimulation was calculated by dividing the total number 
of cells obtained in presence of GSK by the number of cells in control experiments (i.e. EGM-2 MV) 
and multiplying the ratio by 100. The effect of VEGF was evaluated by plating the cells with 10 ng/ml 
VEGF and with or without BAPTA (30 µM), a membrane-permeable intracellular Ca2+ buffer (Dragoni 
et al., 2011; Dragoni et al., 2013). Alternatively, 1 x 105 ECFC-derived cells were plated in 30-mm 
collagen-treated dishes in EGM-2 MV Bullet Kit in the absence (control) and presence of either RN-
1734 (20 µM) or ruthenium red (10 µM), two well known TRPV4 inhibitors. The effect of TRPV4 
blockade on EPC proliferation was evaluated as illustrated above.  
 
Chemicals 
EBM and EGM-2 were purchased from Clonetics (Cell System, St. Katharinen, Germany). 
Fura-2/AM was obtained from Molecular Probes (Molecular Probes Europe BV, Leiden, The 
Netherlands). GSK has been synthesized as described in (Zaninetti et al., 2011). All other chemicals 
were obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
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RESULTS 
 
TRPV4 is expressed in human endothelial colony forming cells 
The expression of TRPV4 mRNA in human EPCs was assessed by RT-PCR. Figure 1A depicts 
the results of agarose gel electrophoresis of representative PCR reaction products. Single bands of the 
expected size of cDNA fragments were amplified (246 and 146 bp for TRPV4 and β-actin, 
respectively) in isolated cells. In the absence of RT, no PCR-amplified products were detected, thereby 
showing the specificity of the reaction (Fig. 1A). These data are consistent with the presence of TRPV4 
mRNA in human EPCs. In order to determine whether TRPV4 is expressed at protein level, we 
performed a Western Blot analysis by using affinity-purified antibodies, which revealed a prominent 
band at 70 kDa (Fig. 1B, right). As a control, we utilized human dermal (HMVEC-d) and coronary 
(HMVEC-c) microvascular endothelial cells, which both display a protein of the same molecular size 
(Fig. 1B, left). Therefore, TRPV4 is present at both mRNA and protein level in circulating EPCs.  
 
TRPV4 agonists elicit intracellular Ca2+ signals in endothelial colony forming cells 
In order to assess whether these TRPV4 proteins conduct extracellular Ca2+, EPCs were loaded 
with Fura-2 and exposed to GSK (20 nM) or PMA (10 µM), two specific TRPV4 agonists (Everaerts et 
al., 2010). As a consequence, GSK has been extensively utilized to assess the biological outcomes of 
TRPV4 activation in vascular endothelium (Mergler et al., 2011; Sonkusare et al., 2012; Sullivan et al., 
2012). Figure 2A shows that GSK evoked a transient increase in [Ca2+]i in 121 out of 125 (96.8%) 
circulating EPCs: the magnitude of the Ca2+ signal was 0.075±0.005 (n=121), whereas the average lag 
time between the exposition to the agonist and the onset of the response was 46.7±1.2 sec (n=121). 
GSK-induced Ca2+ signals were reversibly prevented by removal of extracellular Ca2+ (Fig. 2B) and by 
RN-1734 (20 µM; n=117) (Fig. 2C), a selective TRPV4 antagonist (Bagher et al., 2012; Zheng et al., 
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2013). Ruthenium red (RR) has also been used as a pharmacological tool to validate TRPV4 expression 
in vascular endothelium (Hatano et al., 2013; Willette et al., 2008; Zheng et al., 2013). As expected, the 
Ca2+ response to GSK was reversibly suppressed by pre-incubating the cells with this compound (10 
µM; n=104) (Fig. 2D). 
Subsequently, we probed the effect of PMA, a structurally distinct TRPV4 agonist (Everaerts et 
al., 2010). Figure 3A shows that PMA (10 µM) elicited a rapid and monophasic increase in [Ca2+]i in 
251 out of 306 EPCs (82%). The amplitude of the Ca2+ peak was 0.125±0.007 (n=251), while the 
latency of the signal ranged between 10 sec and 430 sec, the average value being 107.8±78.9 sec 
(n=184). PMA-evoked increase in [Ca2+]i was reversible (Fig. 3B) and disappeared in absence of 
extracellular Ca2+ (Fig. 3C). Notably, readmission of Ca2+ to the bathing solution always restored the 
[Ca2+]i raise (Fig. 2C), as well as removal of extracellular Ca2+ caused the rapid decline of the [Ca2+]i 
elevation to the baseline (Fig. 3D). Similar to GSK, both RN-1734 (20 µM; n=102) (Fig. 3E) and RR 
(10 µM; n=170) (Fig. 3F) abrogated PMA-evoked Ca2+ signals in human EPCs. Consistent with these 
results, the acute application of RR (10 µM) abrogated the Ca2+ response to PMA in 53 out of 53 
(100%) cells (Fig. 3G). Phorbol esters might also stimulate TRPV1 channels (Baylie and Brayden, 
2011), whose transcripts are expressed in circulating EPCs (see Fig. S1). However, PMA-induced Ca2+ 
signals were unaffected by capsazepine (10 µM) (Fig. 3H), a specific TRPV1 inhibitor. This result 
strongly hints at TRPV4 as the molecular target of PMA. Overall, the pharmacological profile (i.e. 
activation by phorbol esters and GSK, and blockade by RN-1734 and RR) herein described concurs 
with that reported in mature human endothelium, at both micro- and macrovascular level (Bubolz et al., 
2012a; Hatano et al., 2013; Pla et al., 2008; Pla et al., 2012b; Sonkusare et al., 2012; Sullivan et al., 
2012), and demonstrate that the TRPV4 protein detected by immunoblotting serves as a Ca2+-
permeable membrane channel in human EPCs. Conversely, neither hypotonic stimulation (n=141) (Fig. 
4A) or 1-2 µM arachidonic acid (AA) (n=102) (Fig. 4B), which have been associated to TRPV4-
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mediated Ca2+ inflow in mature endothelium (Moccia et al., 2012b; Pla et al., 2008), ignited any 
detectable increase in [Ca2+]i in EPCs responsive to 20 nM GSK. 
 
TRPV4-induced Ca2+ inflow is not amplified by intracellular Ca2+ release in EPCs 
Extracellular Ca2+ influx gated through TRPV4 channels may be further amplified by the 
mechanism of Ca2+-induced Ca2+ release (CICR), thereby resulting in a massive Ca2+ mobilization 
from the intracellular Ca2+ pool. For instance, TRPV4-gated Ca2+ influx recruits InsP3-dependent Ca2+ 
release and triggers propagating Ca2+ oscillations in mouse astrocyte endfeet (Dunn et al., 2013). We 
have widely established that the ER Ca2+ content in human EPCs is mainly sensitive to InsP3-
dependent stimulation, while functional ryanodine receptors seem to be absent (Dragoni et al., 2011; 
Dragoni et al., 2013; Lodola et al., 2012; Sánchez-Hernández et al., 2010). In order to assess the 
contribution of the endogenous Ca2+ reservoir to TRPV4-induced Ca2+ signals, we depleted the InsP3-
regulated Ca2+ pool with cyclopiazonic acid (CPA). CPA is a selective inhibitor of Sarco-Endoplasmic 
Reticulum Ca2+-ATPase (SERCA) activity which impairs ER Ca2+ storage ability. The application of 
CPA (10 µM) in the presence of extracellular Ca2+ led to an initial increase in [Ca2+]i due to 
interruption of the ER Ca2+ cycle between SERCA-mediated Ca2+ re-uptake and Ca2+ efflux through 
ER leakage channels. The following decay of the intracellular Ca2+ peak to a plateau level was due to 
SOCE activation following depletion of the intracellular Ca2+ reserve (Lodola et al., 2012; Sánchez-
Hernández et al., 2010). Thirty minutes of pre-treatment with 10 µM CPA have been shown to fully 
empty the InsP3-sensitive Ca2+ store in human EPCs (Dragoni et al., 2011; Sánchez-Hernández et al., 
2010). However, the subsequent addition of GSK (20 nM) caused an increase in [Ca2+]i which did not 
significantly (p<0.05) differ from that observed in untreated cells (Fig. 5A-C). In order to confirm this 
data, we challenged with GSK (20 nM) EPCs pre-incubated with 2-APB (50 µM), a popular InsP3R 
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inhibitor (Dragoni et al., 2011; Dragoni et al., 2013). In according with our previous results, 2-APB did 
not significantly (p<0.05) affect GSK-induced Ca2+ signals in EPCs (Fig. 5E-F). 
 
Effect of TRPV4-mediated Ca2+ entry on EPC proliferation 
TRPV4-mediated Ca2+ entry promotes cell replication in a variety of mature endothelial cells 
(Hatano et al., 2013; Pla et al., 2008; Schierling et al., 2011; Troidl et al., 2010; Troidl et al., 2009). 
Therefore, we focussed on EPC proliferation to evaluate the physiological outcome of TRPV4 
activation. Surprisinly, TRPV4 stimulation with GSK did not cause a statistically relevant (p<0.05) 
increase in cell number, when EPCs were grown in a basal medium devoid of growth factors and 
supplemented with 5% foetal bovine serum (Figure 6A). Our control experiments demonstrated that 
EPC proliferation occurs in a Ca2+-dependent manner when the cells are stimulated with VEGF (10 
ng/ml), as previously reported by our group (Fig. 6B) (Dragoni et al., 2011; Dragoni et al., 2013; 
Lodola et al., 2012; Sánchez-Hernández et al., 2010). Therefore, TRPV4 activation by GSK does not 
lead to cell replication in endothelial committed progenitors. We then sought to assess whether TRPV4 
sustains EPC proliferation during EPC expansion with the EGM-2 MV Bullet Kit. Figure 6C shows 
that RR (10 µM) and RN-1734 (20 µM) cause a modest inhibition in cell growth when compared to the 
dramatic effect exerted by BTP-2 (20 µM), a selective inhibitor of SOCE in EPCs (Lodola et al., 2012; 
Moccia et al., 2012d; Moccia et al., 2014a; Sánchez-Hernández et al., 2010). However, BTP-2 has been 
shown to affects conductances other than Orai1 and TRPC1 in other cellular settings (Moccia et al., 
2012d; Moccia et al., 2014a). Therefore, we confirmed this result by showing that low micromolar 
doses of La3+ and Gd3+, which selectively interfere with SOCE at this concentration (Moccia et al., 
2012d; Moccia et al., 2014a), dramatically reduced cell proliferation (Fig. 6C), as previously shown by 
our group in healthy EPCs (Lodola et al., 2012). These data are consistent with those we have 
previously described in both normal cells and EPCs isolated from RCC patients (Lodola et al., 2012; 
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Sánchez-Hernández et al., 2010): overall, they strongly suggest that SOCE is more powerful in 
delivering pro-angiogenic Ca2+ signals to human EPCs than TRPV4.  
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DISCUSSION 
 
TRPV4 has recently been shown to promote mature EC proliferation both in vitro and in vivo 
due to the activation of a host of Ca2+-dependent transcription factors, such as nuclear factor of 
activated T-cells, calcineurin-dependent 1 (NFATc1), Kv channel interacting protein 3, calsenilin 
(KCNIP3/CSEN/DREAM), and myocyte enhancer factor 2C (MEF2C). Moreover, TRPV4-mediated 
Ca2+ inflow drives TECs to both migrate and replicate, a feature which hints at this channel as a 
suitable target for alternative anti-angiogenic strategies. Apart from the classic process of sprouting 
angiogenesis, tumour vascularization may require the contribution of bone marrow-derived EPCs (Gao 
et al., 2009; Moccia et al., 2014a). We have recently suggested that the pharmacological blockade of 
extracellular Ca2+ inflow might be successfully employed in anti-cancer strategies when the target 
channel is present both in mature ECs and in more immature committed progenitors (Moccia et al., 
2014a).  Therefore, we endeavoured the present investigation to assess whether TRPV4 is expressed 
and controls proliferation in peripheral EPC, the only EPC subset truly belonging to the endothelial 
lineage and to physically engraft within neovessels in vivo. 
 
A functional TRPV4 is expressed in human EPCs 
We provided the evidence that TRPV4 is present in circulating human EPCs at both mRNA and 
protein level. Immunoblotting detected a single band at 70kDa, which is in the same range as that 
reported in human microvascular endothelium (Pla et al., 2012b). Conversely, human coronary ECs 
were recently found to express two TRPV4 bands at 110 and 98 kDa, respectively (Bubolz et al., 
2012b). In this regard, immunoblotting conducted in both kidney extracts (Liedtke and Friedman, 
2003) and rat cholangiocytes (Gradilone et al., 2007) revealed a double band pattern: the 107 kDa 
protein and a shorter 75 kDa isoform. The lower molecular band observed in both EPCs and 
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microvascular ECs might, therefore, be attributed to an alternative splice variant or to post-translational 
modifications of TRPV4. For instance, the anti-TRPV4 immunoblot showed only the 75 kDa band 
when rat cholangiocyte homogenates were treated with N-glycosidase (Gradilone et al., 2007). These 
results indicate that, unlike TRPC3, TRPC5 and TRPC6, TRPV4 is expressed by EPCs before they 
engraft within the foci of neovascularisation. It is, however, likely that specific environmental cues 
instruct EPCs to promote TRPV4 glycosylation when they acquire a macrovascular endothelial 
phenotype (Aird, 2012). The expression of a functional TRPV4 protein in EPCs has then been 
demonstrated by the Ca2+ signals occurring in response to two structurally distinct TRPV4 agonists, 
namely PMA and GSK. Accordingly, both PMA- and GSK-evoked elevations in [Ca2+]i have been 
observed in the presence, but not in the absence, of extracellular Ca2+ and are inhibited by both RR, 
which is an unselective TRPV inhibitor, and RN 1734, which specifically blocks TRPV4. The kinetics 
of the Ca2+ response to PMA and GSK are, however, different. Both compounds have widely been 
employed to assess the expression of a conductive TRPV4 channel in mature ECs both in vitro and in 
vivo (Hatano et al., 2013; Schierling et al., 2011; Troidl et al., 2010; Troidl et al., 2009). Phorbol esters 
activate TRPV4 independently on protein kinase C, i.e. by physically interacting with a binding pocket 
located within the transmembrane III-IV region of the channel protein (Everaerts et al., 2010). 
Conversely, the activating mechanism of GSK is yet to be elucidated. Unlike PMA, the Ca2+ response 
to GSK is transient and rapidly decays to the baseline. The rapid recovery of intracellular Ca2+ in the 
continuous presence of the agonist might be due to GSK-induced channel desensitization, as recently 
described in (Jin et al., 2011). These authors demonstrated that GSK specifically activates TRPV4-
gated Ca2+ inflow, thereafter causing a rapid down-regulation of the plasmalemmal protein that is 
associated to the shut-down of channel activity (Jin et al., 2011). This feature, however, does not apply 
to each vascular district, as human corneal endothelial cells display a sustained increase in [Ca2+]i even 
upon agonist washout (Mergler et al., 2011). As compared to PMA, however, the onset of GSK-
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induced Ca2+ signals is relatively fast. The long delay before the development of the Ca2+ response to 
phorbol esters is a well documented hallmark of TRPV4 signalling (Nilius et al., 2004), and has been 
reported both in micro- and macrovascular endothelial cells (Bubolz et al., 2012a; Pla et al., 2012b). 
This feature is related to the dynamics of actin cytoskeleton: arachidonic acid (AA)-induced actin 
polymerization dramatically reduces the latency distribution of the Ca2+ response to 4αPDD in breast 
tumour-derived endothelial cells (Pla et al., 2012b). Future experiments will have to assess this 
mechanism also in EPCs. 
 
Hypotonic cell swelling and arachidonic acid do not stimulate TRPV4-mediated Ca2+ entry in 
EPCs 
TRPV4 is a polymodal channel that may be also activated by mechanical stimulation and 
endogenous second messengers, such as AA and its metabolites, including epoxyeicosatrienoic acids 
(EETs) (Everaerts et al., 2010; Moccia et al., 2012b). For instance, a hypotonic challenge has been 
shown to produce TRPV4-mediated Ca2+ signals in human corneal endothelial cells  and carotid artery 
endothelial cells (Hartmannsgruber et al., 2007). Similarly, low micromolar doses of AA recruit 
TRPV4 in mouse aortic endothelial cells (Vriens et al., 2004), human coronary ECs (Zheng et al., 
2013) and in B-TECs (Pla et al., 2012b). However, both hypotonic stimulation and low µM doses of 
AA failed to induce intracellular Ca2+ signals in GSK-sensitive EPCs. These results imply a difference 
in the gating mechanism between mature endothelial cells and their committed progenitors. It has been 
suggested that AA and its metabolites bind to a LSRKFKD domain, that is homolog to the archidonate 
recognition sequence (ARS) of melastatin TRPM2 (TRPM2) (ISXXTKE) (Everaerts et al., 2010). 
Alternatively, TRPV4 stimulation by either cell swelling or low µM concentrations of AA may activate 
Ca2+ entry at a lower extent as compared to GSK and PMA, thereby caused a sub-membranal Ca2+ 
elevation that is missed by our Ca2+ imaging system. Whatever its molecular underpinnings, the lack of 
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a Ca2+ response to AA explains EPC insensitivity to hypotonic stress; accordingly, cell swelling elicits 
TRPV4-mediated Ca2+ influx by stimulating phospholipase A2 (PLA2) to produce AA, which is in turn 
metabolized by P450 epoxyoxidases to epoxyeicosatrienoic acids (Everaerts et al., 2010). Thus, if AA 
fails to evoke a detectable increase in [Ca2+]i, neither hypotonic challenge is expected to augment 
intracellular Ca2+ levels. 
 
Intracellular Ca2+ mobilization does not sustain TRPV4-mediated Ca2+ inflow 
We have recently shown that EPCs may utilize extracellular Ca2+ influx to stimulate Ca2+ 
mobilization from the InsP3-sensitive intracellular Ca2+ pool. For instance, in umbilical cord derived-
EPCs, TRPC3 gates an influx of Ca2+ which subsequently promotes InsP3-dependent Ca2+ release 
(Dragoni et al., 2013). However, the depletion of ER Ca2+ pool does not affect the Ca2+ response to 
GSK in their peripheral counterparts. Similarly, the pharmacological inhibition of InsP3Rs does not 
imparir TRPV4-evoked Ca2+ signalling in circulating EPCs. This result concurs with the findings 
reported in endothelial cells of mouse mesenteric arteries (Sonkusare et al., 2012), where TRPV4-
induced Ca2+ inflow is an event temporally and spatially distinct from InsP3-dependent Ca2+ release, 
but not with those described in mouse astrocytes (Dunn et al., 2013). Perivascular astrocytic endfeet 
generate intracellular Ca2+ waves by impinging on the dynamic synergy between TRPV4-mediated 
Ca2+ entry and InsP3-evoked Ca2+ release: these propagated Ca2+ elevations are abrogated by 
superfusing the cells with either CPA or xestospongin C, a well known InsP3R inhibitor. Another 
observation suggests that TRPV4 channels on the plasma membrane are uncoupled from the 
intracellular Ca2+ releasing machinery sitting on the underlying ER membranes. TRPV4 activity is 
potentiated by a modest increase Ca2+ levels in close proximity of the inner mouth of the channel pore, 
while it is inhibited by higher Ca2+ elevations (Everaerts et al., 2010). Conversely, the global elevation 
in [Ca2+]i elicited by SERCA inhibition does not interfere with TRPV4-dependent Ca2+ inflow in EPCs. 
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This feature suggests that this massive [Ca2+]i raise is not translated into a change in Ca2+ concentration 
in vicinity of the COOH-terminal calmodulin-binding site of TRPV4 protein, which senses the changes 
in environmental Ca2+. 
 
TRPV4 plays a minor role in controlling EPC proliferation 
TRPV4-mediated Ca2+ inflow has long been known to control endothelial proliferation and 
vascular remodelling due to the activation of several Ca2+-dependent transcription factors, such as 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1), Kv channel 
interacting protein 3, calsenilin (KCNIP3/CSEN/DREAM), and myocyte enhancer factor 2C (MEF2C) 
(Hatano et al., 2013; Pla et al., 2008; Pla et al., 2012b; Schierling et al., 2011; Thodeti et al., 2009; 
Troidl et al., 2010; Troidl et al., 2009). For instance, TRPV4-dependent Ca2+ signals drive the shear 
stress- and 4αPDD-induced growth of collateral vessels (arteriogenesis) which occurs as a consequence 
of arterial occlusion in a number of vascular districts (Schierling et al., 2011; Troidl et al., 2010; Troidl 
et al., 2009). In addition, TRPV4-induced Ca2+ entry promotes proliferation of human brain capillary 
endothelial cells (Hatano et al., 2013) and of breast tumour-derived endothelial cells (B-TECs) (Pla et 
al., 2008; Pla et al., 2012b). However, selective stimulation of TRPV4 with GSK did not promote EPC 
growth when the cells were plated in the absence of any further growth factor. These results are 
different from those reported in human brain capillary endothelial cells and in B-TECs, which are 
induced to replicate when TRPV4 is stimulated with 4αPDD and AA, respectively (Hatano et al., 2013; 
Pla et al., 2008). Likewise, endothelial cells are prompted to undergo mitosis upon in vivo application 
of 4αPDD in rat carotid artery (Schierling et al., 2011), rabbit femoral artery (Troidl et al., 2009), and 
pig limb arteries (Troidl et al., 2010). Therefore, TRPV4-gated Ca2+ inflow per se does not entail EPC 
proliferation and is likely to require the concomitant activation of additional Ca2+ entry pathways or 
signal transduction cascades. Consistent with this hypothesis, when the cells were expanded in a culture 
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medium supplemented with several growth factors and serum, the pharmacological inhibition of 
TRPV4 with either RR or RN-1734 only partially reduced EPC proliferation. Interestingly, RR exerted 
a stronger effect as compared to RN-1374. However, while the latter is a drug designed to selectively 
impair TRPV4-mediated Ca2+ inflow, the former may affect other TRPV channels. In particular, RR 
may block TRPV1-gated Ca2+ entry in human corneal endothelial cells (Mergler et al., 2011). It is, 
therefore, conceivable that the higher extent of inhibition caused by this compound is due to the 
blockade of a TRPV1-dependent Ca2+ influx. Unlike RR and RN-1734, however, the blockade of 
SOCE with three structurally distinct inhibitors, i.e. BTP-2, La3+ and Gd3+, fully abrogated cell 
replication. Therefore, Orai1 and TRPC1 deliver a more powerful pro-angiogenic Ca2+ stimulus to 
endothelial committed progenitors as compared to TRPV4. It is tempting to speculate that the Ca2+-
sensitive machinery that translates TRPV4-mediated Ca2+ inflow into a mitogenic signal relocates in 
vicinity to the inner mouth of the channel pore only after EPC engraftment into the vasculature and 
subsequent acquisition of a mature endothelial phenotype. Alternatively, we might invoke the recent 
finding that TRPV4 activity is confined to a few sites on the endothelial membrane, even though the 
channel is evenly distributed along the whole cell surface (Sullivan et al., 2012). In this view, the 
agonist-dependent recruitment of TRPV4 channels selectively coupled to the decoders of the 
proliferative stimulus might occur only after full EPC differentiation to endothelial lineage. Yet, future 
studies will have to unveil whether TRPV4 is already capable of triggering NO and/or PGI2 synthesis 
and/or EDHF activation in EPCs as it does in mature endothelium. 
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FIGURE LEGENDS 
 
Figure 1. Expression of TRPV4 transcript and protein in ECFCs. A, gel electrophoresis of 
PCR products. Representative semiquantitative RT-PCR of TRPV4. Reverse transcription was 
performed in the presence (+) or absence (-) of reverse transcriptase enzyme. TRPV4 mRNA 
expression was normalized to β-actin. The 246 and 146 bp bands correspond to the TRPV4 and β-
actin-specific PCR products, respectively. MW: molecular weight marker. B, representative western 
blots showing TRPV4 and β-actin expression in normal human microvascular ECs (HMEVC-d, 
HMEVC-c) and EPCs. 
 
Figure 2. GSK stimulates Ca2+ inflow in EPCs. A, GSK (20 nM) induces a transient elevation 
in [Ca2+]i in EPCs. B, the Ca2+ response to GSK arises in the presence, but not in the absence (0Ca2+), 
of extracellular Ca2+. C, 30 min pre-treatment with RN-1734 (20 µM) inhibits GSK-induced Ca2+ entry, 
which promptly resumes upon drug washout. D, 30 min pre-incubation with ruthenium red (RR; 10 
µM) reversibly prevents GSK-evoked Ca2+ entry. 
 
Figure 3. PMA triggers Ca2+ entry in EPCs. A, PMA (10 µM) evokes a sustained increase in 
[Ca2+]i in circulating EPCs. B, PMA-evoked Ca2+ signals rapidly return to the baseline upon removal of 
the agonist from the bath. C, PMA does not elicit any detectable increase in [Ca2+]i in the absence of 
extracellular Ca2+ (0Ca2+); restitution of Ca2+ to the external solution quickly resumes the Ca2+ 
response. D, removal of extracellular Ca2+ (0Ca2+) reversibly abolishes PMA-induced elevation in 
[Ca2+]i. E, 10 min pre-incubation with ruthenium red (RR; 10 µM) prevents PMA-evoked Ca2+ 
signalling until drug removal from the perfusate. F, the acute addition of ruthenium red (RR; 10 µM) 
abrogates the Ca2+ response to PMA. G, 10 min pre-incubation with capsazepine (10 µM) does not 
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alter PMA-induced increase in [Ca2+]i. H, mean±SE of the amplitude of PMA-evoked Ca2+ signals in 
the presence and absence of capsazepine. 
 
Figure 5. Intracellular Ca2+ mobilization does not support GSK-induced Ca2+ inflow in 
EPCs. Ca2+ response to GSK (20 nM) in the absence (A) and presence of (B) of cyclopiazonic acid 
(CPA; 10 µM), which blocks SERCA activity thereby depleting the endogenous Ca2+ reservoir. C, 
mean±SE of the amplitude of GSK-induced Ca2+ signals under the designated treatments. Ca2+ 
response to GSK (20 nM) in the absence (D) and presence of (E) of 2-APB (50 µM), which blocks 
InsP3Rs and prevents intracellular Ca2+ discharge. F, mean±SE of the amplitude of GSK-induced Ca2+ 
signals under the designated treatments. 
 
Figure 6. The effect GSK, ruthenium red and RN-1734 on EPC proliferation. A, GSK (20 
nM) does not stimulate ECFC proliferation after three days in culture. As a positive control the cells 
have been grown in the presence of the growth factors-enriched medium EGM-2. B, VEGF (10 ng/ml) 
induces ECFC proliferation in the absence, but not in the presence, of BAPTA (30 µM). BAPTA was 
added 30 min before challenging the cells with VEGF to buffer intracellular Ca2+ levels, as shown in 
(Dragoni et a., 2011). C, mean±SE of the percentage of EPC growth in the presence of EGM-2, 
ruthenium red (RR; 10 µM), RN-1734 (20 µM; RN), BTP-2 (20 µM), La3+ (10 µM) and Gd3+ (10 µM). 
*, compared with control and after Bonferroni’s correction (Student’s t test for unpaired samples). 
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